Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
Richard Benjamin, Chief Medical Officer at Cerus Corporation, shared on LinkedIn:
”The results of the ReCePI Phase III clinical study are now published.
A hearty congratulations to the many contributors and patients who have advanced the field of pathogen reduction for red blood cells (RBCs).
While transfusions are generally considered safe, they are always at risk for newly emerging infections (think historically of HIV, WNV, Zika, etc.) and for threats that are not covered by current testing (e.g., bacteria, malaria, etc.).
Technologies are FDA-approved to safeguard platelet and plasma transfusions, leaving an obvious gap with the most commonly transfused RBC components.
This work is bringing RBC pathogen reduction to reality and would not have been possible without generous funding from BARDA, a US agency with true foresight to protect patients against future and current threats to transfusion safety.”
Read the full article here.
Article: Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Authors: Michael E. Sekela, Edward L. Snyder, Ian J. Welsby, Yoshiya Toyoda, Mohamed Alsammak, Neel R. Sodha, Thomas M. Beaver, J. Peter R. Pelletier, James D. Gorham, John S. McNeil, Roman M. Sniecinski, Ronald G. Pearl, Gregory A. Nuttall, Ravi Sarode, T. Brett Reece, Richard Benjamin, and the ReCePI Study Collaborators
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe LippiÖ‰ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India
-
Oct 20, 2026, 03:31Zena Vexler: Targeting Neutrophil Elastase and NETosis to Mitigate Infection-Triggered Childhood Stroke